Mercury Laboratories Limited
Latest filings
- HR Manager Jaydeepsinh Raj ceased duties with effect from October 28, 2026 · Management Changes
- Reg 74(5) Demat Compliance Certificate for Jul-Sep 2026 Quarter · Compliance
- Non-Executive Director not re-appointed by shareholders at AGM · Management Changes
Snapshot
What the business is, and whether it's a good one at a fair price.
Manufactures pharmaceutical products as its single business segment, operating from at least one plant at Jarod (Gujarat, where the company has a Plant Head role on record). FY26 total income was Rs 75.94 crore, with net profit of Rs 4.83 crore and an EBITDA margin of 13.96%. The filings repeatedly describe the business as a one-segment pharmaceutical products company, with no breakdown of therapy area, formulation type, or geography of sale provided. In Q1 FY27, revenue from operations was about Rs 579 lakh and net profit was Rs 12.47 lakh. The largest cost line is raw materials at 33.4% of revenue, followed by employee cost at 23.0% and other operating expenses at 26.3%; depreciation is 4.5% and capex is 4.2% of revenue, indicating a relatively asset-light cost base. Outstanding borrowings stood at Rs 7.31 crore as of March 31, 2026, and the company's fixed deposit programme carries a CRISIL rating of BB+/Stable. The Board recommended a final dividend of Rs 3.50 per share (35% of face value) for FY26.
Scorecard
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
Strengths
Concerns
Charts
How has the market priced it — with filings on the timeline?
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from Mercury Laboratories Limited's filed financials and exchange disclosures
What does Mercury Laboratories Limited do?
Mercury Laboratories Limited is a Pharmaceuticals & Biotechnology company listed on BSE.
Is Mercury Laboratories Limited profitable?
Yes. Over the trailing twelve months Mercury Laboratories Limited reported a net profit of ₹4.16 Cr on revenue of ₹74 Cr.
Does Mercury Laboratories Limited pay a dividend?
Yes. The dividend yield is 0.47% at the current price. It paid out 9% of its profit as dividend in FY26.
Is Mercury Laboratories Limited debt-free?
No. It reported borrowings of ₹7.41 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹6.61 Cr after cash. Debt stands at 0.13× equity. That is lower than 53% of its 166 Pharmaceuticals peers.
Is Mercury Laboratories Limited expensive compared with its peers?
On trailing P/E, Mercury Laboratories Limited ranks 53 of 158 in Pharmaceuticals — cheaper than 67% of them, against an industry median of 30.8×. This is a position, not a valuation judgement.
How much does the Mercury Laboratories Limited share price move in a day?
On a typical session Mercury Laboratories Limited moves 1.50% — that is the median absolute close-to-close move across its last 227 trading days. MarketPing measures each filing's price reaction against it.
Where can I track Mercury Laboratories Limited's announcements?
Every NSE and BSE filing by Mercury Laboratories Limited appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.